SCI 발표논문

SCI 발표논문

← SCI 발표논문 목록

Br J Cancer. 2008;98(6):1118-24.

High tumour islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected non-small cell lung cancer.

, , , , , , , , , , , , , ,

제1저자 김동완 · 교신저자 허대석

소속 (1)
  1. Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.

Abstract

The purpose of this study was to investigate the prognostic value of tumour-associated macrophages with a focus on micro-anatomical localisation and determine whether molecular changes of the epidermal growth factor receptor (EGFR) are related to macrophage infiltration in resected non-small cell lung cancer (NSCLC). One hundred and forty-four patients were included in this study. Immunohistochemistry was used to identify CD68+ macrophages in the tumour islet and surrounding stroma. Epidermal growth factor receptor mutations were studied by direct sequencing. The EGFR gene copy number and protein expression were analysed by fluorescence in situ hybridisation and immunohistochemistry. Patients with a high tumour islet macrophage density survived longer than did the patient with a low tumour islet macrophage density (5-year overall survival rate was 63.9 vs 38.9%, P=0.0002). A multivariate Cox proportional hazard analysis revealed that the tumour islet macrophage count was an independent prognostic factor for survival (hazard ratio 0.471, 95% confidence interval 0.300-0.740). However, EGFR mutations, gene copy number, and protein expression were not related to the macrophage infiltration. In conclusion, tumour islet macrophage infiltration was identified as a strong favourable independent prognostic marker for survival but not correlated with the molecular changes of the EGFR in patients with resected NSCLC.

Figures

Figure 1
Figure 1 Immunohistochemistry demonstrating the presence of CD68+ macrophages (brown) in (A) tumour islet and (B) tumour stroma (× 200).
Figure 2
Figure 2 Kaplan–Meier overall survival curves stratified according to the tumour islet macrophage density (A) and stromal macrophage density (B).
Figure 3
Figure 3 Kaplan–Meier overall survival curves stratified according to the tumour islet and stromal macrophage density (A) and total (tumour islet plus stromal) macrophage density (B). Group 1 (n=29): patients with high tumour islet and low stromal macrophage density; Group 2 (n=43): patients with high tumour islet and high stromal macrophage density; Group 3 (n=43): patients with low tumour islet and low stromal macrophage density; Group 4 (n=29): patients with low tumour islet and high stromal macrophage density.
Figure 4
Figure 4 Kaplan–Meier overall survival curves stratified according to the TNM stage groups (A) and complete resection status (B).

그림 출처: PubMed Central 공개 논문 (PMC2275476)

그 밖의 정보
출판 형태
Journal Article, Research Support, Non-U.S. Gov't
저널
British journal of cancer · ISSN 0007-0920
전자 출판
2008-02-19
MeSH
Aged · Antigens, CD / analysis · Antigens, Differentiation, Myelomonocytic / analysis · Carcinoma, Non-Small-Cell Lung / genetics / pathology · Cell Count · ErbB Receptors / metabolism · Female · Gene Dosage* · Genes, erbB-1* · Humans · Lung Neoplasms / genetics / pathology · Macrophages / immunology · Male · Middle Aged · Mutation* · Prognosis · Survival Analysis · CD68 Molecule
Substances
Antigens, CD · Antigens, Differentiation, Myelomonocytic · ErbB Receptors · CD68 antigen, human · CD68 Molecule
참고문헌
24편